A Phase I/II Dose-Escalation and Expansion Study of the Selective PKC-β Inhibitor MS-553 in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Acalabrutinib (Primary) ; MS 553 (Primary) ; Obinutuzumab (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors MingSight Pharmaceuticals
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Mar 2023 Planned End Date changed from 25 May 2023 to 15 Jun 2024.
- 13 Mar 2023 Planned primary completion date changed from 4 Feb 2023 to 15 Apr 2024.